Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
03:57am, Wednesday, 27'th Nov 2024
Shares of Amgen (AMGN -4.76%) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-o
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond
06:32pm, Tuesday, 26'th Nov 2024
Piper Sandler's Christopher Raymond joins 'Fast Money' to talk Amgen's stock sinking on GLP-1 results.
Amgen: MariTide Underwhelms, But There Are Ways To Win
03:03pm, Tuesday, 26'th Nov 2024
Shares of Amgen fell after the company reported underwhelming phase 2 data with weight loss up to 20% in obese patients after 52 weeks of treatment. The results underperformed Street expectations. I b
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
02:40pm, Tuesday, 26'th Nov 2024
Amgen (AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations.
Chart of the Day: Amgen
01:10pm, Tuesday, 26'th Nov 2024
Amgen on pace for its worst day since October of 2000. It's our Chart of the Day.
S&P, Nasdaq climb while Dow dips amid Trump tariff concerns; Amgen, Kohl's shares tumble
12:12pm, Tuesday, 26'th Nov 2024
The S&P 500 and Nasdaq Composite rose on Tuesday, while Dow Jones slipped as investors assessed the threat of new tariffs from President-elect Donald Trump. The S&P 500 index rose 0.2%, while the Na
Amgen tumbles to year's low despite weightloss trial success
11:07am, Tuesday, 26'th Nov 2024
Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares tumbled 11.6% to a year's low after results of a trial for its potential weight-loss drug showed it helped overweight or obese people lose up 20% of weight ov
Cramer's Stop Trading: Amgen
10:24am, Tuesday, 26'th Nov 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of Amgen.
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
08:36am, Tuesday, 26'th Nov 2024
On Tuesday, Amgen Inc AMGN stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in o
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
08:32am, Tuesday, 26'th Nov 2024
The pharmaceutical company's MariTide treatment performed well in a phase 2 study.
Amgen's stock slides 7.8% after weight-loss drug data lags analyst expectations
08:05am, Tuesday, 26'th Nov 2024
Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25%.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
07:53am, Tuesday, 26'th Nov 2024
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
07:14am, Tuesday, 26'th Nov 2024
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But the results appear to be a
Amgen drug leads to up to 20% weight loss in trial
07:10am, Tuesday, 26'th Nov 2024
Amgen's experimental drug MariTide led to average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
07:05am, Tuesday, 26'th Nov 2024
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less
